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This essay presents a short historical perspective on B1 cells and a synopsis of 
contemporary work in my laboratory on generating B1 cells from B2 cells via B cell 
receptor exchange. 
 
 
This lecture is a tribute to a great scientist and longtime friend, Len Herzenberg from 
Stanford University. As a young group leader at the Institute for Genetics in Cologne, 
founded by Max Delbrück after the war, I had met Len in the early 1970s at a meeting in 
the German Democratic Republic, and thus began a friendship lasting until Len’s death in 
2013. Naturally, this included Lee Herzenberg, the central person at this first World 
Congress on B1 cells here in Tarrytown, New York. For a long time, Len’s and Lee’s 
house in Palo Alto became a second home for me, and I can remember many endless 
discussions with Lee about her beloved B1 cells deep into the night. Len was not only a 
famous geneticist and immunologist, but also a wonderful human being of a limitless 
curiosity and broad worldview, and one of the first scientists from the U.S. in my field 
actively supporting and helping the new generation of scientists in postwar Germany. It 
was through him that I realized early on the power of fluorescence-activated cell sorting 
in combination with monoclonal antibodies, and it was with his help that we acquired, at 
our young institute in Cologne, what I think was the fourth FACS machine produced by 
Becton-Dickinson. In technical terms, this provided the basis for our own work on B1 
cells, which was of course inspired by the work of the Herzenbergs and their colleagues. 
 From the very beginning, the relationship of B1 and the classical B2 cells was at 
the center of our interest in that context, as it was for most others in the field. Did B1 
		 2
cells represent a separate B cell “lineage,” perhaps of fetal origin, or was B1 
differentiation driven by the engagement of certain self-antigens with a particular set of B 
cell receptor (BCR) specificities recognizing epitopes shared by common pathogens in 
the environment, and thus recruited into an innate system of first-line defense? While not 
mutually exclusive, the latter view was supported by evidence for the selection of 
particular BCR specificities in the B1 cell compartment, and the dominant contribution of 
these cells to natural antibodies in the blood (for review of the older literature, see Refs. 
1–3). While the field has moved forward substantially over the past decades, as can be 
seen by comparing the proceedings of the 1992 conference on B1 cells published at the 
time in Annals of the New York Academy of Sciences4 with the proceedings of the 2014 
conference also published in Annals5, several of the issues mentioned above have still not 
been fully resolved, one of them being the role of BCR specificity and self-antigen 
recognition in the acquisition of the B1 cell phenotype. This problem has occupied 
myself and collaborators in my group over many years, and most of my lecture at the 
Merinoff World Congress 2014: B-1 Cell Development and Function in Tarrytown, New 
Yorka–– summarized below––dealt with this work, which is still ongoing.  
 
Pathways of B1 cell generation 
Early work of my group had shown that B1 cells do not only arise from fetal but also 
from postfetal progenitors. This became apparent from the accumulation of N sequences 
at the V–D and D–J borders of VDJ rearrangements carried by B1 cells at different times 
in ontogeny. Whereas such sequences are essentially absent from VDJ rearrangements of 
B cells isolated from fetal or newborn mice, they accumulate in both B1 and B2 cells 
subsequently, albeit at lower tempo in the B1 compartment.6,7 This is due to the postnatal 
expression of TdT in the cells, a developmental feature shared between B1 and B2 cells. 
While this result did not directly address the B1/B2 lineage problem, it would be 
compatible with the notion that B1 cells could be generated in two different ways, 
namely, (1) from a perhaps distinct fetal B1 cell precursor and (2) from B2 cells through 
a particular type of activation through the BCR.  
																																																								
a	http://molmed.org/events/world‐congress/2014		
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 At that time, conditional gene targeting had been established in my laboratory in 
Cologne, and we decided to use this approach to genetically address whether a B2 cell 
could be converted into a B1 cell by exchanging its BCR with a B1-typical BCR that 
recognized an epitope shared among self-antigens and bacterial pathogens. This work 
was initiated in Cologne by Kong Peng Lam, continued at Harvard Medical School by 
Jane Seagal and Kevin Otipoby, and is presently being pushed ahead by Robin Graf, after 
my move from Boston to the Max Delbrück Center at the end of 2011 (a manuscript 
describing the results should be submitted for publication within this year). 
 At this stage, the results of the work in progress can be summarized as follows: 
upon the induced exchange of a B2-typical transgenic BCR (through which mature B 
cells had been generated in vivo) with a phosphatidyl-choline (PtC)–specific B1-typical 
BCR (whose expression in the germ line results in a pure B1a B cell compartment in the 
mouse), the PtC-specific B cells undergo several rounds of rapid cell division in vivo over 
a period of a few days, and then persist as resting cells in the spleen and, abundantly, the 
peritoneal cavity of the recipient (syngeneic) animals. Significantly, the cells 
phenotypically convert to a B1a phenotype in terms of cell surface and other markers, 
and exhibit B1a-typical survival and response properties. 
 While we do not know whether and to what extent B2-to-B1 cell conversion plays 
a role in normal physiology, as a reflection of the response of B cells to particular stimuli, 
the data clearly indicate that B2 cells have the capacity to convert to B1 cells both 
phenotypically and, at least in part, functionally. It is tempting to think that the 
mechanisms controlling this differentiation process similarly operate in fetal B1 cell 
differentiation. Perhaps, as discussed by David Nemazee at the 2014 conference, B1 
lineage progenitors (for whose existence there is now strong evidence5) have a propensity 
to respond to certain self-antigens in the	sense	of positive selection rather than tolerance, 
like immature B2 cells; while mature B2 cells behave like B1 progenitors if exposed to 
these same antigens. 
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